4.7 Article

Multi-targeting liposomal codelivery of cisplatin and rapamycin inhibits pancreatic cancer growth and metastasis through stromal modulation

Journal

INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 644, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ijpharm.2023.123316

Keywords

ATF24 peptide; Co-delivery; Rapamycin; Cisplatin; Liposomes; Pancreatic cancer; Liver metastasis

Ask authors/readers for more resources

Pancreatic cancer treatment is hindered by drug resistance and liver metastasis. A new strategy, combination therapy, was developed to address these challenges. By using ATF peptide-decorated liposomal co-loaded with cisplatin and rapamycin, the delivery of drugs to tumor cells was significantly improved, leading to enhanced therapeutic effects in vitro and in vivo. This multi-targeting nanomedicine may provide a new approach for treating metastatic pancreatic cancer.
Pancreatic cancer treatment faces challenges due to drug resistance as well as liver metastasis. As a new strategy for treating pancreatic cancer, combination therapy is now available, but the dense mesenchymal barrier in the tumor tissue blocks drug delivery and impairs its therapeutic efficacy. To address this issue, we prepared an ATF peptide-decorated liposomal co-loaded with cisplatin and rapamycin (ATF@Pt/Rapa Lps), which targets both tumor cells and cancer-associated fibroblasts that express uPAR receptors. In tumor sphere penetration experiments, ATF peptide modified liposomes significantly enhanced deep penetration. More importantly, the ATF@Pt/Rapa Lps disrupted the stroma, as demonstrated by the downregulation of alpha-SMA, I collagen, and fibronectin protein in vivo and in vitro. In this way, highly effective drug delivery to tumor cells can be achieved. As expected, there was a stronger inhibition of cell proliferation and migration by ATF@Pt/Rapa Lps in vitro compared to free Pt/Rapa and Pt/Rapa Lps. Furthermore, ATF@Pt/Rapa Lps showed greater therapeutic effects in PANC02 transplanted tumor mice and liver metastasis mice models. Ultimately, multi-targeting nanomedicines co-loaded with Rapa and cisplatin may provide a new approach to treating metastatic pancreatic cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available